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Abstract
Objective
YKL-40, a chitinase-like glycoprotein associated with inflammation and tissue remodeling,
is produced by joint tissues and recognized as a candidate auto-antigen in rheumatoid
arthritis (RA). In the present study, we investigated YKL-40 as a potential biomarker of dis-
ease activity in patients with early RA at baseline and during intensive treatment aiming for
early remission.
Methods
Ninety-nine patients with early DMARD-naïve RA participated in the NEO-RACo study. For
the first four weeks, the patients were treated with the combination of sulphasalazine, meth-
otrexate, hydroxychloroquine and low dose prednisolone (FIN-RACo DMARD combination),
and subsequently randomized to receive placebo or infliximab added on the treatment for
further 22 weeks. Disease activity was evaluated using the 28-joint disease activity score
and plasma YKL-40 concentrations were measured by immunoassay.
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Results
At the baseline, plasma YKL-40 concentration was 57 ± 37 (mean ± SD) ng/ml. YKL-40 was
significantly associated with the disease activity score, interleukin-6 and erythrocyte sedi-
mentation rate both at the baseline and during the 26 weeks’ treatment. The csDMARD
combination decreased YKL-40 levels already during the first four weeks of treatment, and
there was no further reduction when the tumour necrosis factor-α antagonist infliximab was
added on the combination treatment.
Conclusions
High YKL-40 levels were found to be associated with disease activity in early DMARD-naïve
RA and during intensive treat-to-target therapy. The present results suggest YKL-40 as a
useful biomarker of disease activity in RA to be used to steer treatment towards remission.
Introduction
YKL-40 is an inflammation-associated glycoprotein with a molecular weight of 40 kDa. It
belongs to the family of chitinase like proteins but lacks the enzymatic activity of true chiti-
nases. YKL-40 is known also by names chitinase-3-like protein 1 (Chi3-l1), breast regression
protein 39 (BRP-39), human cartilage glycoprotein 39, and chondrex. It is expressed in various
cell types and increased levels of YKL-40 have been linked to inflammation, tissue remodeling
and cancer, but the exact biological activities are yet to be identified [1].
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting principally the joints,
but the mechanisms that trigger the autoimmune responses leading eventually to joint destruc-
tion are not fully known. At early phases of the process, exogenous and autologous antigens
are presented to T-cells by antigen presenting cells and interestingly, YKL-40 is recognized as
a candidate autoantigen [2–6]. Circulating YKL-40 levels have been shown to be higher in RA
patients as compared to healthy controls [7–13]. Also, the YKL-40 concentrations in synovial
fluid (SF) are higher than those measured in plasma indicating significant intra-articular pro-
duction [7,11]. Within RA joints, YKL-40 has been recognized as a major secretory protein of
articular chondrocytes [14]. Synovial cells, macrophages and neutrophils infiltrating into the
RA synovium also produce YKL-40 [1,14–16], and just recently, splenic T-cells have been
added to the list of YKL-40 producing cells in RA [17].
In the treatment of RA, the current treat-to-target approach aims for early remission
or maximally low disease activity. Biological disease modifying anti-rheumatic drugs
(bDMARDs), including tumour necrosis factor-α (TNF-α) inhibitors, are recommended to be
commenced with conventional systemic disease-modifying antirheumatic drugs (csDMARDs)
if the treatment target is not reached with csDMARDs alone [18]. In RA, assessment of disease
activity is based on composite indices, such as the 28-joint disease activity score (DAS28) [19]
evaluating the count of tender and swollen joints, inflammation and patient´s assessment of
the disease activity. We have reported previously based on the current NEO-RACo trial [20–
23] excellent sustained clinical results with treat-to-target approach in patients with early,
DMARD-naïve RA by using the intensified Finnish Rheumatoid Arthritis combination (FIN-
RACo) treatment. This consists of a combination of three csDMARDs (i.e. sulphasalazine,
methotrexate and hydroxychloroquine) and low dose glucocorticoid (GC) following a prede-
fined protocol supplemented with active treatment of inflamed joints with intra-articular GC
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injections [24]. At 2 years, DAS28 remission was achieved in 82% of the patients [20]. Adding
infliximab to the FIN-RACo combination treatment for the first 6 months in a randomized,
double-blind and parallel-group manner, induced remission more rapidly, but differences
between the treatment groups were not statistical significant at 2 or 5 years follow-up [20,21].
In the search of novel biomarkers, we hypothesized that YKL-40, an inflammatory factor
produced mainly by intra-articular tissues, could reflect disease activity and inflammation in
RA patients. In the present study, we tested this hypothesis by measuring the YKL-40 plasma
levels in DMARD-naïve patients at the baseline and during intensive anti-rheumatic treatment
in the NEO-RACo study.
Methods
Study design, patients, outcomes and follow-up
Ninety-nine (99) patients with early active RA fulfilling the classification criteria positioned by
ACR [25] were recruited into this investigator initiated multicenter study between March 2003
and April 2005. NEO-RACo study is a prospective 5 year trial, with extension to 10 years. Fol-
low-up was completed in 2015 after which secondary endpoint analyses were performed.
Patients were treated with an intensified FIN-RACo combination including sulphasalazine (up
to a maximum of 2 g/day), methotrexate (up to a maximum of 25 mg/week), hydroxychloro-
quine (35 mg/kg/week), and prednisolone (7.5 mg/day) and double blindly randomized to
receive in allocation ratio 1:1 infusions of either placebo (solvent without active drug) or inflix-
imab (3 mg/kg), at weeks 4, 6, 10, 18 and 26. The patients were stratified according to seroposi-
tivity (rheumatoid factor defined in a local accredited laboratory). The randomisation was
performed centrally by an external laboratory not participating in the clinical trial in blocks of
10 patients. As part of the protocol, all inflamed joints were actively treated with intra-articular
injections of glucocorticoids. After 24 months, if the patient was in remission, prednisolone
and DMARDs were gradually tapered off with a predefined protocol or in the case of non-
remission medication was modified according to the judgment of the treating rheumatologist
aiming at strict remission.
The DAS28 score (ESR) was used to evaluate disease activity [19]. The modified Sharp-van
der Heijde score was used to evaluate radiologic score [26]. The patient selection criteria as
well as the treatment protocol, outcomes and follow-up have been described earlier [20–23].
The study was conducted according to the Declaration of Helsinki. All patients gave
informed written consent. The study protocol was approved by the ethics committee of the
Hospital District of Helsinki and Uusimaa (statement number 676/E5/02, date January 14,
2002) and registered at Helsinki University Central Hospital HUCH Study Register (date April
29, 2003). The study was registered at the Clinical Trials Database (https://clinicaltrials.gov/
ct2/show/NCT00908089?term=NCT00908089&rank=1) in 2009, soon after the revision of the
Declaration of Helsinki in 2008, which promoted trial registration in a publicly accessible data-
base. The authors confirm that all ongoing and related trials for this drug/intervention are
registered.
Plasma samples and ELISA
Plasma samples were collected at weeks 0, 4, 10, 18, 26 (all time points were available from 88
patients, 60 females, Fig 1) and kept at -80˚C until assayed. The concentrations of YKL-40 and
matrix metalloproteinase-3 (MMP-3) (R&D Systems, Minneapolis, MN, USA), and interleu-
kin-6 (IL-6) (eBioScience Inc., San Diego, CA, USA) were measured by ELISA following the
instructions of the manufacturer.
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Statistics
Results are expressed as medians with interquartile ranges (IQRs) or means with standard
deviations (SDs) or 95% confidence intervals (95% CIs). Statistical comparisons between the
groups were carried out by using t-test, bootstrap type t test (5000 replications) or chi-square
test, when appropriate. Analysis of repeated data was carried out by using generalizing estimat-
ing equations (GEE) with the unstructured correlation structure. Generalized estimating equa-
tions were developed as an extension of the general linear model (e.g. OLS regression analysis)
to analyze longitudinal and other correlated data. In longitudinal GEE analyses, DAS28 and its
components were used as outcome variables, YKL-40 and time as covariates and the model
was adjusted with age, gender, rheumatoid factor positivity and treatment. In the case of viola-
tion of the assumptions (e.g. non-normality), a bootstrap-type test was used (5 000 replica-
tions). Area under the curve (AUC) was calculated with the trapezoidal method over the time
Fig 1. CONSORT flow diagram for the NEO-RACo study.
https://doi.org/10.1371/journal.pone.0183294.g001
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points from 0 to 26 weeks. A possible non-linear relationships between YKL40(AUC) and
DAS28(AUC) and IL-6(AUC) was assessed by using regression models with quadratic term.
Correlation coefficients were calculated by the Spearman method. The normality of the vari-
ables was tested by using the Shapiro-Wilk W test. STATA software (version 13.1, StataCorp,
LP, Texas, USA) was used in the statistical analysis.
Results
At the baseline, YKL-40 concentration in the DMARD-naïve RA patients was 57 ± 37 ng/ml
(mean ± SD, n = 88) and there was no differences between females and males (55 ± 37 ng/ml,
n = 60 vs 61 ± 38 ng/ml, p = 0.43). Characteristics of the patients are shown in Table 1. The lev-
els of YKL-40 under baseline conditions correlated positively with the disease activity mea-
sured as DAS28 score (r = 0.41, p<0.001, Fig 2A). When the DAS28 components were
assessed separately, the baseline YKL-40 correlated positively with the count of tender joints
(r = 0.28, p = 0.004, Fig 2B) and ESR (r = 0.50, p<0.001, Fig 2C), but there was no correlation
with the count of swollen joints or patient´s global assessment of general health. Proinflamma-
tory cytokine IL-6 as well as MMP-3 showed a positive correlation with YKL-40 at the baseline
(r = 0.30, p = 0.004, Fig 2D and r = 0.39, p<0.001, Fig 2E, respectively).
The patients received a combination of sulphasalazine, methotrexate, hydroxychloroquine
and low dose prednisolone for the first four weeks following the intensified FIN-RACo combi-
nation treatment strategy [24]. Subsequently, the patients were randomized to receive inflixi-
mab or placebo, which was added on the csDMARD combination treatment for the further 22
weeks.
Table 1. The baseline characteristics of the patients.
Characteristic The initial randomization group P-value All
FIN-RACo + Infliximab (n = 44) FIN-RACo + Placebo (n = 44) (n = 88)
Demographic data at baseline
Female, no (%) 32 (73) 28 (64) 0.41 60 (68)
Age (years), mean ± SD years 47 ± 9 44 ± 11 0.22 46 ± 10)
Duration of symptoms (months), median (IQR) 4 (2, 5) 4 (3, 6) 0.54 4 (2, 6)
Rheumatoid factor present (%) 35 (80) 32 (73) 0.56 67 (76)
Measures of disease activity at baseline
Swollen joint count, mean ± SD 14 ± 5 16 ± 8 0.33 15 ± 6
Tender joint count, mean ± SD 18 ± 9 21 ± 11 0.10 20 ± 10
Erythrocyte sedimentation rate (mm/h), mean ± SD 33 ± 20 33 ± 23 0.84 33 ± 21
Patient’s global assessment (VAS, mm), mean ± SD 49 ± 25 47 ± 28 0.71 48 ± 26
Pain (VAS, mm), mean ± SD 52 ± 28 51 ± 28 0.79 52 ± 27
Physician’s global assessment (VAS, mm), mean ± SD 46 ± 20 53 ± 20 0.12 50 ± 20
DAS28, mean ± SD 5.4 ± 1.0 5.6 ±1.4 0.66 5.5 ± 1.2
Physical function (HAQ), mean ± SD 1.0 ± 0.6 0.9 ± 0.7 0.47 0.9 ± 0.7
Radiography at baseline
Erosion score*, mean ± SD 2.5 ± 7.1 1.9 ± 4.4 0.66 2.2 ± 5.9
Narrowing score*, mean ± SD 0.5 ± 1.6 0.3 ± 0.7 0.48 0.4 ± 1.2
Total score, mean ± SD 3.0 ± 8.3 2.1 ± 4.7 0.62 2.6 ± 6.7
Statistical comparison between the groups was performed by t-test, bootstrap-type t-test (5000 replications), or chi-square test, when appropriate.
* Radiologic score by modified Sharp-van der Heijde score.
https://doi.org/10.1371/journal.pone.0183294.t001
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During the first four weeks of treatment with the csDMARD combination, YKL-40 levels
decreased significantly (p<0.001, Fig 3). This decrease in YKL-40 levels showed a positive cor-
relation to the change in IL-6 (r = 0.38, 95% CI: 0.18, 0.54) as well as the change in MMP-3 lev-
els (r = 0.42, 95% CI: 0.23, 0.58) from baseline to four weeks; whereas no correlation to the
change in DAS28 was found.
During the following 22 weeks of treatment with csDMARD ± infliximab, YKL-40 levels
showed a minor further decrease (groups combined: -5.0 ng/ml, 95%CI: -9.6 to -0.5,
p = 0.031). However, there was no difference in YKL-40 levels between placebo and infliximab
treated groups over time (Fig 3). The result together suggest that decrease in YKL-40 levels is
related to the antirheumatic effect of DMARDs, not to infliximab treatment per se.
To assess the associations of YKL-40 with disease activity over time (during the 26 weeks of
treatment), area under curve (AUC) analysis adjusted for age, gender and rheumatoid factor
(RF) positivity was used. A significant correlation between DAS28 AUC0-26 weeks and YKL-40
AUC0-26 weeks (r = 0.41, p<0.001) was found as shown in Fig 4A. Similarly, during the 26
Fig 2. YKL-40 was associated with disease activity, IL-6 and MMP-3 in the DMARD-naïve RA patients. The figure shows scatter plots of YKL-40
levels with disease activity measured as DAS28 (A), tender joint count (B), erythrocyte sedimentation rate (C), IL-6 (D), and MMP-3 (E) at the baseline.
Correlation coefficients were calculated by the Spearman method. YKL-40 showed positive correlation to DAS28, tender joint count, ESR, IL-6 and MMP-
3 at the baseline.
https://doi.org/10.1371/journal.pone.0183294.g002
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weeks’ treatment, YKL-40 AUC0-26 weeks showed a significant positive correlation to ESR
AUC0-26 weeks (r = 0.56, p<0.001), PGA AUC0-26 weeks (r = 0.23, p = 0.035) as well as to IL-6
AUC0-26 weeks (r = 0.31, p = 0.004, Fig 4B). These results were confirmed in longitudinal gener-
alized estimating equation model (GEE, adjusted for treatment group as well as for age, gender
and rheumatoid factor) where YKL-40 showed a significant independent association with
Fig 3. YKL-40 levels decreased during the intensive anti-rheumatic treatment with a combination of
csDMARDs. The figure shows the mean change in plasma YKL-40 levels in 88 patients in the NEO-RACo
-study treated with a combination of sulphasalazine, methotrexate, hydroxychloroquine and low dose
prednisolone for the first four weeks, and thereafter randomized to receive either placebo infusions (Fin-RACo
+ Pla) or infliximab infusions (Fin-RACo + INFL) added on the csDMARD combination for another 22 weeks.
YKL-40 levels decreased significantly (p<0.001) during the first four weeks of treatment with csDMARDs;
when infliximab (or placebo) was added to the treatment there was a minor further decrease (groups
combined, p = 0.031) but no difference between placebo and infliximab treatment groups was found. The
change is presented as ng/ml, mean ± 95% CI, n = 88.
https://doi.org/10.1371/journal.pone.0183294.g003
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Fig 4. YKL-40 was associated with disease activity and inflammation during intensive treatment with
DMARDs. The figure shows quadratic relationships of YKL-40 with the disease activity measured as DAS28
(A) and with the inflammatory cytokine IL-6 (B) during the 26 weeks of treatment. The patients were treated for
the first four weeks with a combination of sulphasalazine, methotrexate, hydroxychloroquine and low dose
prednisolone, and thereafter randomized to receive either placebo infusions or infliximab infusions added to
YKL-40 as a biomarker of disease activity in rheumatoid arthritis
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DAS28, and associated most potently with ESR and PGA when the individual measures of this
variable were analyzed (Table 2).
Discussion
In the present study, we found that high YKL-40 levels were associated with more severe
inflammation and with disease activity in DMARD naïve patients with early RA, as well as in
the same patients during 26 weeks’ intensive anti-rheumatic treatment. YKL-40 is thus pro-
posed as a potential biomarker of disease activity and inflammation not only in early treatment
naïve RA, but also during active drug treatment aiming for remission.
YKL-40 is present in RA joints and its concentrations in synovial fluid are higher than
those in serum indicating intra-articular synthesis of the glycoprotein [7,11]. Possible intra-
articular cell types producing YKL-40 are fibroblast-like synovial cells, macrophages, neutro-
phils and chondrocytes [1,11,27]. Hypomethylated DNA loci of the YKL-40 gene were recently
detected in synovial cells from RA patients and this epigenetic change was presented to lead to
the overexpression of the gene [28]. Also, peripheral blood derived CD16 positive mononu-
clear cells with a macrophage phenotype infiltrating into the synovium are another potential
cellular source of YKL-40 in RA [15]. In addition, lymphocytes may produce YKL-40: Recent
study by Tanaka et al. using glucose-6-phospatase isomerase immunized mice as a model of
RA, showed overexpression of YKL-40 in splenic regulatory T cells [17].
The cellular effects of YKL-40 are not, however, known very well. It may be that YKL-40
itself is not the functional effector molecule but a precursor. To support that assumption,
YKL-40 derived peptides have been shown to induce T-cell proliferation in RA patients [2].
Antigen presenting cells (APCs) from RA synovial fluid were reported to process YKL-40 and
present the decay peptides to T-cells [6]. This was associated with the RA-related HLA-DR4
phenotype, and especially the peptide 259–271 was found to induce T-cell proliferation
[2,6,29]. Also, the immune response was shifted towards the proinflammatory Th1 type reac-
tion by YKL-40 in patients with RA, but not in healthy controls [5]. Further, T-lymphocytes
with RA-associated HLA-DR4 alleles were reported to produce high amounts of interferon-γ
and TNF-α when re-exposed to YKL-40 derived peptides, while the production of these
cytokines in T-cells with HLA-alleles non-associated to RA was very low [29]. Moreover,
the treatment for another 22 weeks. Measurements were carried out at weeks 0, 4, 10, 18, and 26 during the
treatment and area under the curve analysis over time (AUC0-26 weeks) adjusted for age, gender and RF
positivity was used. Gray-shaded areas represent 95% confidence intervals around the mean. YKL-40
AUC0-26 weeks showed a statistically significant correlation to DAS28 AUC0-26 weeks and IL-6 AUC0-26 weeks.
https://doi.org/10.1371/journal.pone.0183294.g004
Table 2. Generalized estimating equations models for the effect of YKL40, time and interaction in measures of disease activity from baseline to 26
weeks.
DAS28 TJC SJC ESR PGA
B (95% CI) p-value B (95% CI) p-value B (95% CI) p-value B (95% CI) p-value B (95% CI) p-value
YKL-40 0.03
(0.02 to 0.04)
<0.001 0.08
(0.04 to 0.12)
<0.001 0.07
(0.03 to 0.10)
<0.001 0.32
(0.20 to 0.44)
<0.001 0.29
(0.15 to 0.43)
<0.001
Time -0.10
(-0.12 to -0.08)
<0.001 -0.17
(-0.25 to -0.09)
<0.001 -0.16
(-0.22 to -0.10)
<0.001 -0.31
(-0.52 to -0.10)
0.004 -0.84
(-1.17 to -0.51)
<0.001
TimexYKL-40 0.24 <0.001 0.004 0.017 0.073
Models were adjusted using age, gender, rheumatoid factor positivity and treatment. DAS28—disease activity score in 28 joints, TJC—tender joint count,
SJC—swollen joint count, ESR—erythrocyte sedimentation rate, PGA—patient´s global assessment.
https://doi.org/10.1371/journal.pone.0183294.t002
YKL-40 as a biomarker of disease activity in rheumatoid arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183294 August 25, 2017 9 / 15
complexes of MHC and YKL-40 derived peptides were detected in synovium samples from
RA patients and found to associate with characteristic features of rheumatoid synovitis [30].
Also, a positive association between YKL-40 expression in synovial mononuclear cells and
joint destruction was reported [15].
There is substantial variability in circulating YKL-40 levels between RA patients, as also
found in the present study. In addition to inflammatory joint diseases, increased levels of
YKL-40 have been found in other diseases characterized by inflammation and tissue remodel-
ing like asthma, COPD, liver fibrosis, and cancer [1,27]. In addition, certain single nucleotide
polymorphisms (SNPs) in the YKL-40 gene have been studied: Nielsen et al. investigated the
SNPs in the YKL-40 gene in RA patients and found SNPs that were associated with increased
levels of serum YKL-40 but not with RF positivity [31]. However, the frequencies of the investi-
gated SNPs did not differ between RA patients and controls in that study or in the study by Sri-
vastava et al. [31,32].
In the present study, YKL-40 correlated with inflammatory markers IL-6 and ESR both at
baseline and during active treatment. To support our data, previous studies based on analysis
in a single time point, serum YKL-40 levels have also been shown to associate with ESR and
CRP as well as the proinflammatory cytokine IL-6 in RA patients [2,10,33]. The present study
extends the previous data by showing that when assessed over time and based on AUC mea-
surements during 26 weeks’ follow-up, YKL-40 correlated with disease activity and inflamma-
tion also during the intensive treatment with a combination of DMARDs and infliximab.
YKL-40 correlated also with the disease activity as measured by DAS28 score, at the baseline
and during active anti-rheumatic treatment. Similarly to our results, serum YKL-40 was
reported to be associated with DAS28 at baseline in DMARD-naïve patients in the study by
Knudsen et al. [12] and in a single measurement during DMARD monotherapy reported by
Bakker et al. [34]. Also, Kazakova et al., who studied RA patients with active disease despite of
on-going DMARD treatment, found a positive correlation between serum YKL-40 and syno-
vial thickening and vascularization depicting synovial inflammation, although no correlation
between serum YKL-40 and DAS28 was reported [13]. There are also two other studies based
on single measurements of serum YKL-40 during DMARD monotherapy which failed to find
correlation between circulating YKL-40 concentrations and the number of swollen or painful
joints [8,33]. While the studies by Johansen et al. [9,35] and Peltomaa et al. [10] in addition to
the previously mentioned study by Bakker et al [34], which followed early RA patients receiv-
ing DMARD monotherapy, showed a positive correlation of the swollen joint count to YKL-
40 supporting the present findings.
In the present study, baseline YKL-40 correlated positively also with MMP-3. MMP-3 has
been reported to be associated with the disease activity and to predict radiological progression
in RA [36]. Previously, we have shown that YKL-40 correlates positively with MMP-3 in syno-
vial fluid and cartilage of OA patients [27].
In the present study, YKL-40 levels decreased significantly during active anti-rheumatic
treatment based on intensified Finnish Rheumatoid Arthritis combination (FIN-RACo) ther-
apy [24]. The FIN-RACo regimen consists of a combination of sulphasalazine, methotrexate,
hydroxychloroquine and low dose prednisolone supplemented with active treatment of
inflamed joints with intra-articular glucocorticoids. The detected decrease in YKL-40 levels
reflects the anti-inflammatory effect achieved with the active treatment, which results in excel-
lent sustained clinical results and minimal radiological progression of the disease in long-term
follow-up as recently reported by us [20,21]. Johansen et al. [35] reported that YKL-40 levels
decreased more rapidly in patients receiving high dose prednisolone together with a DMARD
than is patients treated with a DMARD only; in that study, it was also found that methotrexate
decreased YKL-40 levels more rapidly than other DMARDs. In addition, intra-articular
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glucocorticoid injections have been shown to decrease serum YKL-40 levels rapidly and the
levels increased when the joint inflammation regained [11].
When the TNF-α antagonist infliximab was added to the intensive csDMARD combination
therapy in the present patients, it did not cause any further decrease in the YKL-40 levels. This is
presumably because the patients were already on the active FIN-RACo-combination treatment
and had an excellent treatment response. The absent effect of infliximab on YKL-40 levels is also
in agreement with the previous study, in which intravenously given TNF-α did not have any
effect on plasma YKL-40 levels in healthy volunteers [37]. There are also studies in which TNF-
α antagonists have been shown to decrease YKL-40 levels in RA patients [38–40]. In those stud-
ies, however, csDMARDS and glucocorticoids were not used as actively as in the present study
where FIN-RACo combination treatment was supplemented with infliximab in a randomized
and placebo-controlled manner. The decrease in the YKL-40 levels is thus likely due to anti-
inflammatory treatment response itself rather than a direct TNF-α antagonist effect on the YKL-
40 levels. This is supported by the finding reported in patients with spondyloarthritis (SpA)
treated with TNF-α antagonist: serum YKL-40 concentrations decreased during successful anti-
TNF-α treatment whereas YKL-40 levels remained high in non-responding patients [41].
In the present study we investigated the potential of YKL-40 as a single biomarker in early
RA. This is advantageous over multibiomarker disease activity tests (MBDA) not only because
of its inexpensiveness but also as biologicals/tsDMARDs have been shown to have compensa-
tory increasing effects on the levels of the individual cytokines/mediators included in the
MBDA set which may result in underestimation of clinical responses to the treatments. For
instance, in the ACT-RAY study, blocking of IL-6 receptor with tocilizumab increased IL-6
levels over 400% [42]. In another study, RA patients treated with a janus kinase 1/3 signaling
inhibitor tofacitinib had significantly increased leptin levels [43]. The increasing effect of tofa-
citinib on leptin levels may be a compensatory mechanism as leptin signals through leptin
receptor (ObR) activating JAK/STAT pathway. Most recently, the Vectra DA MBDA-test
failed to reflect clinical disease activity in the AMPLE trial during the treatment with abatacept,
an inhibitor of T-cell activation, or adalimumab, an anti-TNF agent [44].
The present results, together with the previously published data, suggest that glycoprotein
YKL-40 may be used as a biomarker of disease activity in RA, both in the early disease in treat-
ment naïve patients and during active treatment with DMARD combination with or without
infliximab.
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